1. BRCA1 Promoter Hypermethylation is Associated with Good Prognosis and Chemosensitivity in Triple-Negative Breast Cancer
   William Jacot et al, 2020, Cancers CrossRef
2. Prognostic epigenetics
   Adriana Fodor et al, 2021, Medical Epigenetics CrossRef
3. Prognostic Effects of RASSF1A, BRCA1, APC, and p16 Promoter Methylation in Ovarian Cancer: A Meta-Analysis
   Cheng Chen et al, 2024, Gynecologic and Obstetric Investigation CrossRef
4. CDH22 hypermethylation is an independent prognostic biomarker in breast cancer
   Esperanza Martín-Sánchez et al, 2017, Clinical Epigenetics CrossRef
5. Levels of DNA Methylation Vary at CpG Sites across the BRCA1 Promoter, and Differ According to Triple Negative and “BRCA-Like” Status, in Both Blood and Tumour DNA
   Sarah L. Daniels et al, 2016, PLOS ONE CrossRef
6. Long-term outcomes of young, node-negative, chemotherapy-naïve, triple-negative breast cancer patients according to BRCA1 status
   Yuwei Wang et al, 2024, BMC Medicine CrossRef
7. Hypermethylation of CDKN2A exon 2 in tumor, tumor-adjacent and tumor-distant tissues from breast cancer patients
   Melanie Spitzwieser et al, 2017, BMC Cancer CrossRef
8. Trojan-Like Peptide Drug Conjugate Design and Construction for Application in Treatment of Triple-Negative Breast Cancer
   Chuanguang Xiao et al, 2021, Journal of Biomedical Nanotechnology CrossRef
9. CHL1 hypermethylation as a potential biomarker of poor prognosis in breast cancer
   Esperanza Martín-Sánchez et al, 2017, Oncotarget CrossRef